Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 11, 2002 - Issue 12
Submit an article Journal homepage
30
Views
8
CrossRef citations to date
0
Altmetric
Review

Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention

David G Menter The University of Texas M.D., Anderson Cancer Center, Box 236, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Pages 1749-1764 | Published online: 24 Feb 2005

Bibliography

  • HLA T, BISHOP-BAILEY D, LIU C, SCHAEFERS H, TRIFAN 0: Cyclooxygenase-1 and -2 isoenzymes. hat. J. Biochem. Cell Biol. (1999) 31:551–557.
  • MARNETT L: Structure, function and inhibition of cyclo-oxygenases. Ernst Schering Res. Found Workshop (2000) 31:65–83.
  • •Relates the structure of COX enzymes to function and specific effects of inhibitors.
  • SMITH W, DEWITT D, GARAVITO R: Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev Biochem. (2000) 69:145–182.
  • •Examines COX inhibitors and the structure and mechanistic function of COX and peroxidase catalysis.
  • VANE J, BAKHLE Y, BOTTING R: Cyclooxygenases 1 and 2. Ann. Rev Phannacol Toxicol (1998) 38:97–120.
  • KURUMBAIL R, KIEFER J, MARNETT L: Cyclooxygenase enzymes: Catalysis and inhibition. Curc Opin. Struct. Biol. (2001) 11:752–760.
  • •Describes the spectroscopic and crystallographic structural basis for the kinetics and the complex mechanisms of COX inhibition.
  • MARNETT L, DUBOIS R: Cox-2: A target for colon cancer prevention. Ann. Rev. Pharmacol Toxicol (2002) 42:55–80.
  • •Relates COX-2 structure and function to COX-2 selective drug development and colon cancer prevention.
  • CAO Y, PRESCOTT S: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. Cell Physiol (2002) 190:279–286.
  • BISHOP-BAILEY D, CALATAYUD S, WARNER T, HLA T, MITCHELL J: Prostaglandins and the regulation of tumor growth. J. Environ. Pathol Toxicol Oncol (2002) 21:93–101.
  • DUBOIS R, ABRAMSON S, CROFFORD L et al.: Cyclooxygenase in biology and disease. FASEB J. (1998) 12:1063–1073.
  • GATELY S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev (2000) 19:19–27.
  • XU X: Cox-2 inhibitors in cancer treatmentand prevention, a recent development. Anti-Cancer Drugs (2002) 13:127–137.
  • •Discussion of NSAIDs and COX-2 inhibitors in the treatment and prevention of cancers of the colon, oesophagus, lung, bladder, breast and prostate.
  • DANNENBERG A, ALTORKI N, BOYLE J et al.: Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer. Lancet Oncol (2001) 2:544–551.
  • •An important discussion of COX-2 as a pharmacological target to prevent cancer.
  • STRATTON M, ALBERTS D: Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Duntingt) (2002) 16:37–51.
  • •Describes COX-2 involvement in cancer and related clinical trials testing COX-2 inhibitors for chemoprevention.
  • KOKI A, MASFERRER J: Celecwdb: A specific COX-2 inhibitor with anticancer properties. Cancer Control (2002) 9:28–35.
  • TURINI M, DUBOIS R: Cyclooxygenase-
  • A therapeutic target. Ann. Rev Med. (2002) 53:35–57.
  • •A sununary of the role of COX-1 and -2 in normal physiology and disease.
  • BRASH A: Arachidonic acid as a bioactive molecule.j Clin. Invest. (2001) 107:1339–1345.
  • •An important overview of AA metabolism.
  • FITZPATRICK F, SOBERMAN R: Regulated formation of eicosanoids. j Clin. Invest. (2001) 107:1347–1351.
  • BREYER R: Prostaglandin ep(1) receptor subtype selectivity takes shape. Mol Pharmacol (2001) 59:1357–1359.
  • FUNK C: Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science (2001) 294:1871–1875.
  • •Important overview of eicosanoid biology.
  • CLARKE S: Polyunsaturated fatty acid regulation of gene transcription: A molecular mechanism to improve the metabolic syndrome. j. Num. (2001) 131:1129–1132.
  • KLIEWER S, XU H, LAMBERT M, WILLSON T: Perwdsome proliferator-activated receptors: From genes to physiology. Recent Frog. Dorm. Res. (2001) 56:239–263.
  • CHINETTI G, FRUCHART J, STAELS B: Perwdsome proliferator-activated receptors (PPARs): Nuclear receptors with functions in the vascular wall. Z Kardiol (2001) 90:125–132.
  • LIM H, GUPTA R, MAW, PARIA B, MOLLER D, MORROW J et al: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev. (1999) 13:1561–1574.
  • LIM H, DEY S: Minireview: A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology (2002) 143:3207–3210.
  • NIE D, HONN K: Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Ma Life Sci. (2002) 59:799–807.
  • •Examines the regulation of angiogenesis by arachidonate metabolites.
  • NIE D, CHE M, GRIGNON D, TANG K, HONN K: Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev (2001) 20:195–206.
  • CROFFORD L: Prostaglandin biology. Gastroentera Clin. North Am. (2001) 30:863–876.
  • KURUMBAIL R, STEVENS A, GIERSE J et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644–648.
  • •Reported the 3 to 2.5 A resolution crystal structures of unliganded and liganded murine COX-2, which helped explain the structural basis for the selective inhibition of COX–2.
  • PICOT D, LOLL P, GARAVITO R: The X-ray crystal structure of the membrane protein prostaglandin h2 synthase-1. Nature (1994) 367:243–249.
  • •The 3.5 A resolution structure of COX-1 defining the epidermal growth factor domain, the membrane-binding motif and the enzymatic domain.
  • PICOT D, GARAVITO R: Prostaglandin h synthase: Implications for membrane structure. FEBS Lett. (1994) 346:21–25.
  • MARNETT L, KALGUTKAR A: Cyclooxygenase 2 inhibitors: Discovery, selectivity and the future. Trends Pharmacol Sci. (1999) 20:465–469.
  • TOH H: Prostaglandin endoperwdde synthase contains an egf-like domain. FEBS Lett. (1989) 258:317–319.
  • •First report that COX-2 shares sequence homology with EGF in the N-terminal region.
  • MORITA I, SCHINDLER M, REGIER M, OTTO J, HORI T, DEWITT D et al: Different intracellular locations for prostaglandin endoperoxide h synthase-1 and -2. J. Biol. Chem. (1995) 270:10902–10908.
  • •Examined the intracellular locations of COX-1 and -2 showing COX-1 equally distributed in the ER and NE, while COX-2 was twice as concentrated in the NE as in the ER.
  • LI Y, SMITH T, GRABSKI S, DEWITT D: The membrane association sequences of the prostaglandin endoperoxide synthases-1 and -2 isozymes." Biol. Chem. (1998) 273:29830–29837.
  • •Confirmed that the arnphipathic helices present near the amino terminus of COX-1 and -2 act as membrane anchors.
  • ROWLINSON S, CREWS B, GOODWIN D, SCHNEIDER C, GIERSE J, MARNETT L: Spatial requirements for 15- (r) -hydroxy-5 z, 8z,11z, 13e-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-(r)-hete. J. Biol. Chem. (2000) 275:6586-6591. Demonstrated that COX-1 and -2 acetylation by aspirin at Ser530 and Ser516, respectively, completely inactivates COX-1 while altering COX-2 product formation to hydroxyeicosatetraenoic acids (HETEs). This study also showed that AA orients into an L-shaped binding configuration during synthesis of both PGs and HETEs.
  • LEDNICER D: Tracing the origins of COX-2 inhibitors' structures. Curr. Med. Chem. (2002) 9:1457–1461.
  • LOLL P, PICOT D, EKABO 0, GARAVITO R: Synthesis and use of iodinated nonsteroidal antfinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry (1996) 35:7330–7340.
  • LOLL P, PICOT D, GARAVITO R: The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol. (1995) 2:637–643.
  • •A 3.4 A resolution X-ray crystal structure of COX-1 inactivation by the potent aspirin analogue 2-bromoacetoxy-benzoic acid.
  • KALGUTKAR A, KOZAK K, CREWS B, HOCHGESANG G, JR, MARNETT L: Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. Med. Chem. (1998) 41:4800–4818.
  • •Structural analysis of selective covalent modification of COX-2 by a novel inactivator, 2-acetoxyphenyl hept-2-ynyl sulfide (70).
  • MANCINI J, RIENDEAU D, FALGUEYRET J, VICKERS P, O'NEILL G: Arginine 120 of prostaglandin g/h synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. j Biol. Chem. (1995) 270:29372–29377.
  • •Described the importance of the Arg120 residue in COX-1 for the binding of AA and NSAIDs.
  • ROTH G, STANFORD N, MAJERUS P: Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. USA (1975) 72:3073–3076.
  • •Showed that aspirin acetylates the active site of COX.
  • MARNETT L, ROWLINSON S, GOODWIN D, KALGUTKAR A, LANZO C: Arachidonic acid oxygenation by COX-1 and -2. Mechanisms of catalysis and inhibition. I Biol. Chem. (1999) 274:22903–22906.
  • MARNETT L: Cyclooxygenase mechanisms. Cum Opin. Chem. Biol. (2000) 4:545–552.
  • PALOMER A, CABRE F, PASCUAL J et al.: Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. I Med. Chem. (2002) 45:1402–1411.
  • MEADE E, SMITH W, DEWITT D: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. I Biol. Chem. (1993) 268:6610–6614.
  • SMITH W, MEADE E, DEWITT D: Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann. NY Acad. Sci. (1994) 714:136–142.
  • COLE P, SONDHI D, KIM K: Chemical approaches to the study of protein tyrosine kinases and their implications for mechanism and inhibitor design. Pharmacol Ther: (1999) 82:219–229.
  • JASCHKE A, SEELIG B: Evolution of DNA and ma as catalysts for chemical reactions. Curi: Opin. Chem. Biol. (2000) 4:257–262.
  • KAGAN V, TYURINA Y: Recycling and redox cycling of phenolic antioxidants. Ann. NY Acad. Sci. (1998) 854:425–434.
  • BRUICE T, BENKOVIC S: Chemical basis for enzyme catalysis. Biochemistry (2000) 39:6267–6274.
  • MEYER J, MANNING M: Hydrophobic ion pairing: Altering the solubility properties of biomolecules. Pharm. Res. (1998) 15:188–193.
  • ORLICH B, SCHOMACKER R: Enzyme catalysis in reverse micelles. Adv. Biochem. Eng. Biotechnol (2002) 75:185–208.
  • HELMS V: Electronic excitations of biomolecules studied by quantum chemistry. Curi: Opin. Smuct. Biol. (2002) 12:169–175.
  • YIN MJ, YAMAMOTO Y, GAYNOR RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of i(kappa)b kinase-beta. Nature (1998) 396:77–80.
  • YAMAMOTO Y, YIN MJ, LIN KM, GAYNOR RB: Sulindac inhibits activation of the nf-kappab pathway. I Biol. Chem. (1999) 274:27307–27314.
  • JIANG X, LAM S, LIN M et at.: Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor sc-236 through a protein kinase c-beta(1)-dependent pathway. Oncogene (2002) 21:6113–6122.
  • DEGUCHI A, SOH J, LI H, PAMUKCU R, THOMPSON W, WEINSTEIN I: Vasodilator-stimulated phosphoprotein (vasp) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase Gl. MM. Cancer Ther. (2002) 1:803–809.
  • HSU A, CHING T, WANG D, SONG X, RAN GNEKAR V, CHEN C: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of bc1-2. ./. Biol. Chem. (2000) 275:11397–11403.
  • SHUREIQI I, CHEN D, LOTAN R et at.: 15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. (2000) 60:6846–6850.
  • •Demonstrated that NSAIDs can induce apoptosis in colon cancer cells via up-regulation of 15-LOX-1 in the absence of COX–2.
  • SHUREIQI I, CHEN D, LEE J et al: 15-lox-1: A novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J. Natl. Cancerinst. (2000) 92:1136–1142.
  • HUANG J, WELCH J, RICOTE M et al.: Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 400:378–382.
  • SUBBARAMAIAH K, LIN D, HART J, DANNENBERG A: Perwdsome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and creb-binding protein/p300. J. Biol. Chem. (2001) 276:12440–12448.
  • •Illustrates the involvement of activator protein-1 (AP-1) and CBP/p300 in the suppression of COX-2 synthesis.
  • LANGENBACH R, LOFTIN C, LEE C, TIANO H: Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. NY Acad. Sci. (1999) 889:52–61.
  • WILLIAMS C, MANN M, DUBOIS R: The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 18:7908–7916.
  • BOLD, ROWLEY R, HO C et al.: Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. (2002) 62:2516–2521.
  • •Transgenic K14.00X2 mouse model for COX-2 overexpression that has a protective effect in skin.
  • MULLER-DECKER K, NEUFANG G, BERGER I, NEUMANN M, MARKS F, FURSTENBERGER G: Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc. Nati Acad. Sci. USA (2002) 99(19):12483–12488.
  • DINCHUK J, CAR B, FOCHT R et al.: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase ii. Nature (1995) 378:406–409.
  • •First description of Cox-2 (-I-) mice in which gene loss did not alter inflammatory responses, but females were infertile and gene loss mitigated endotoxin-induced hepatocellular cytotoxicity.
  • BALLOU L, BOTTING R, GOORHA S, ZHANG J, VANE J: Nociception in cyclooxygenase isozyme-deficient mice. Proc. Natl. Acad. Sci. USA (2000) 97:10272–10276.
  • •Examined COX-1- or -2-deficient homozygous and heterozygous mice concluded that PGs made by COX-1 are involved in pain transmission, whereas those made by COX-2 play a role in the stretching responses.
  • WILLIAMS C, TSUJII M, REESE J, DEY SK, DUBOIS R: Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. (2000) 105:1589–1594.
  • •Lewis lung carcinoma tumour growth was attenuated by COX-2 inhibitors or when injected into COX-2(-0, but not COX-1(-/-) or wild-type mice.
  • ZHANG X, MORHAM S, LANGENBACH R, BAGGS R, YOUNG D: Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp. Cell Res. (2000) 254:232–240.
  • •COX-1 and -2 deficient ES cells injections into syngeneic mice revealed COX-2 -I-deficiency leads to more differentiated tumours compared to COX-1(-/-) or wild-type cells and COX-2 is necessary for the efficient growth of teratocarcinomas in animals.
  • BOUTWELL R, VERMA A, ASHENDEL C, ASTRUP E: Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis. Carcinog. Comm: Surv. (1982) 7:1–12.
  • STRINGFELLOW D: Prostaglandins and metastasis. Symp. Fundarn. Cancer Res. (1983) 36:123–131.
  • MARKS F, FURSTENBERGER G: Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learnt by comparing mouse skin carcinogenesis and human large bowel cancer. Eur. Cancer (2000) 36:314–329.
  • SHOEMAKER A, GOULD K, LUONGO C, MOSER A, DOVE W: Studies of neoplasia in the min mouse. Biochim. Biophys. Acta (1997) 1332:F25–F48.
  • OSHIMA M, TAKETO M: COX selectivity and animal models for colon cancer. Curr. Pharm. Des. (2002) 8:1021–1034.
  • NISHIMURA G, YANOMA S, MIZUNO H, KAWAKAMI K, TSUKUDA M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J. Cancer Res. (1999) 90:1152–1162.
  • ALEXANDER J: Use of transgenic mice inidentifying chemopreventive agents. Toxicol. Lett. (2000) 112–113:507–512.
  • THUN M, NAMBOODIRI M, CALLE E, FLANDERS W, HEATH C, JR: Aspirin use and risk of fatal cancer. Cancer Res. (1993) 53:1322–1327.
  • THUN M, CALLE E, NAMBOODIRI M et al.: Risk factors for fatal colon cancer in a large prospective study. Natl. Cancer Inst. (1992) 84:1491–1500.
  • •Cancer prevention study that showed that regular users of low doses of aspirin were at lower risk for developing colon cancer.
  • THUN M, NAMBOODIRI M, HEATH C Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl. J. Med. (1991) 325:1593–1596.
  • •In a study of case and control subjects, regular aspirin use at low doses reduced the risk of fatal colon cancer.
  • GIOVANNUCCI E: The prevention of colorectal cancer by aspirin use. Biomed. Pharmacother. (1999) 53:303–308.
  • GIOVANNUCCI E, EGAN K, HUNTER D et al.: Aspirin and the risk of colorectal cancer in women. N. Engl. J Med. (1995) 333:609–614.
  • GIOVANNUCCI E, RIMM E, STAMPFER M, COLDITZ G, ASCHERIO A, WILLETT W: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. (1994) 121:241–246.
  • SMALLEY W, DUBOIS R:Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Phannacol (1997) 39:1–20.
  • EGAN K, STAMPFER M, GIOVANNUCCI E, ROSNER B, COLDITZ G: Prospective study of regular aspirin use and the risk of breast cancer. j Natl. Cancer Inst. (1996) 88:988–993.
  • HARRIS R, NAMBOODIRI K, FARRAR W: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology (1996) 7:203–205.
  • HABEL L, ZHAOW, STANFORD J: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the us. Cancer Causes Control (2002) 13:427–434.
  • NORRISH A, JACKSON R, MCRAE C: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer (1998) 77:511–515.
  • WADDELL W, GANSER G, CERISE E, LOUGHRY R: Sulindac for polyposis of the colon. Am. J. Surg. (1989) 157:175–179.
  • WADDELL W, LOUGHRY R: Sulindac for polyposis of the colon. J Surg. Oncol. (1983) 24:83–87.
  • GIARDIELLO F, YANG V, HYLIND L et al.: Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl. J. Med. (2002) 346:1054–1059.
  • GIARDIELLO FM, HAMILTON S, KRUSH A et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl. J. Med. (1993) 328:1313–1316.
  • OSHIMA M, DINCHUK J, KARGMAN S et al.: Suppression of intestinal polyposis in apc delta716 knockout mice by inhibition of cyclooxygenase 2 (cox-2). Cell (1996) 87:803–809.
  • •Determined the effects of COX-2 gene (Ptgs2) knockouts and a COX-2 inhibitor on Apc(delta716) knockout mice, a model of human FAP.
  • JACOBY R, SEIBERT K, COLE C, KELLOFF G, LUBET R: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. (2000) 60:5040–5044.
  • OSHIMA M, MURAI N, KARGMAN S et al.: Chemoprevention of intestinal polyposis in the apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. (2001) 61:1733–1740.
  • GIARDIELLO F, OFFERHAUS G, DUB OIS R: The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur. J Cancer (1995) 31A:1071–1076.
  • PHILLIPS R, WALLACE M, LYNCH P et al.: A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Cut (2002) 50:857–860.
  • •A randomised controlled clinical trial found a significant reduction in duodenal polyposis after 6 months of treatment with celecoxib 400 mg bid.
  • STEINBACH G, LYNCH P, PHILLIPS R et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. J. Med. (2000) 342:1946–1952.
  • •In patients with FAP, 6 months of twice-daily treatment with 400 mg of celecoxib reduced colorectal polyp formation.
  • FUNKHOUSER E, SHARP G: Aspirin and reduced risk of esophageal carcinoma. Cancer (1995) 76:1116–1119.
  • FARROW D, VAUGHAN T, HANSTEN P, STANFORD J, RISCH H, GAMMON M et aL:Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarker s Prev. (1998) 7:97–102.
  • RUBIO C: Antitumoral activity of indomethacin on experimental esophageal tumors. J Nati Cancer Inst. (1984) 72:705–707.
  • LI M, SONGS, LIPPMAN S et al: Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene (2002) 21:411–418.
  • LI M, LOTAN R, LEVIN B, TAHARA E, LIPPMAN S, XU X: Aspirin induction of apoptosis in esophageal cancer:A potential for chemoprevention. Cancer Epidemiol. Biomarker s Prey. (2000) 9:545–549.
  • LI M, WU X, XU XC: Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS-398 through a cytochrome c-dependent pathway in esophageal cancer cells. Int. Cancer (2001) 93:218–223.
  • SONGS, XU XC: Effect of benzoralpyrene diol epoxide on expression of retinoic acid receptor-beta in immortalized esophageal epithelial cells and esophageal cancer cells. Biochem. Biophys. Res. Commun. (2001) 281:872–877.
  • SOUZA RE SHEWMAKE K, BEER DG, CRYER B, SPECHLER SJ: Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. (2000) 60:5767–5772.
  • MARKS R:The epidemiology of non-melanoma skin cancer: Who, why and what can we do about it. Dermatol (1995) 22:853–857.
  • JIANG W, ANANTHASWAMY H, MULLER H, KRIPKE M: P53 protects against skin cancer induction by UV-I3 radiation. Oncogene (1999) 18:4247–4253.
  • NGHIEM D, KAZIMI N, CLYDESDALE G, ANANTHASWAMY H, KRIPKE M, ULLRICH S: Ultraviolet a radiation suppresses an established immune response:Implications for sunscreen design. Invest. Dermatol (2001) 117:1193–1199.
  • FISCHER S:Is cyclooxygenase-2 important in skin carcinogenesis?j Environ. Athol Toxicol Oncol (2002) 21:183–191.
  • CHEN W, TANG Q, GONZALES M, BOWDEN G: Role of p38 map kinases and erk in mediating ultraviolet-b induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene (2001) 20:3921–3926.
  • •Showed that activation of p38 is required for UV-B-induced COX-2 gene expression in human keratinocytes.
  • BUCKMAN S, GRESHAM A, HALE P et al.: Cox-2 expression is induced by uvb exposure in human skin:Implications for the development of skin cancer. Carcinogenesis (1998) 19:723–729.
  • HORIO T, MIYAUCHI-HASHIMOTO H, KUWAMOTO K, HORIKI S, OKAMOTO H, TANAKA K: Photobiologic and photoimmunologic characteristics of xpa gene-deficient mice.' in vestig. DerIllata SyMp. PrOC. (2001) 6:58–63.
  • WOLFF H, SAUKKONEN K, ANTTILA S, KARJALAINEN A, VAINIO H, RISTIMAKI A: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. (1998) 58:4997–5001.
  • WATKINS D, LENZO J, SEGAL A, GARLEPP M, THOMPSON P: Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. Ear: Respir (1999) 14:412–418.
  • TSUBOUCHI Y, MUKAI S, KAWAHITO Y et atMeloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. (2000) 20:2867–2872.
  • HASTURK S, KEMP B, KALAPURAKAL S, KURIE J, HONG W, LEE J: Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer (2002) 94:1023–1031.
  • TAKAHASHI T, KOZAKI K, YATABE Y, ACHIWA H, HIDA T: Increased expression of COX-2 in the development of human lung cancers. .1 Environ. Athol Toxicol Oncol (2002) 21:177–181.
  • MOODY T, LEYTON J, ZAKOWICZ H et al.: Indomethacin reduces lung adenoma number in ALI mice. Anticancer Res. (2001) 21:1749–1755.
  • MASFERRERJ, LEAHY K, KOKI A et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. (2000) 60:1306–1311.
  • OGURI T, FUJIWARA Y, OCHIAI M et al.: Expression of lung-resistance protein gene is not associated with platinum drug exposure in lung cancer. Anticancer Res. (1998) 18:4159–4162.
  • HOSOMI Y, YOKOSE T, HIROSE Y et al.: Increased cyclooxygenase 2 (cox-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer (2000) 30:73–81.
  • MUTOH M, WATANABE K, KITAMURA T et al.: Involvement of prostaglandin e receptor subtype ep(4) in colon carcinogenesis. Cancer Res. (2002) 62:28–32.
  • ACHIWA H, YATABE Y, HIDA T et al: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clio. Cancer Res. (1999) 5:1001–1005.
  • HIDA T, YATABE Y, ACHIWA H et al.: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. (1998) 58:3761–3764.
  • KHURI F, WU H, LEE J et a/.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage in non-small cell lung cancer. Clin. Cancer Res. (2001) 7:861–867.
  • SUBBARAYAN V, SABICHI A, LLANSA N, LIPPMAN S, MENTER D: Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res. (2001) 61:2720–2726.
  • •COX-2 expression, although high in normal prostate epithelial cells and low in prostate cancer cells, is induced by TNF-a and this responsiveness may play an important role in prostate cancer progression.
  • SHAPPELL S, MANNING S, BOEGLIN W et al.: Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 3:287–303.
  • TANJI N, KIKUGAWA T, YOKOYAMA M: Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and bc1-2 protein expression. Anticancer Res. (2000) 20:2313–2319.
  • YOSHIMURA R, SANO H, MASUDA C et al.: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer (2000) 89:589–596.
  • GUPTA S, SRIVASTAVA M, AHMAD N, BOST WICK D, MUKHTAR H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate (2000) 42:73–78.
  • KIRSCHENBAUM A, KLAUSNER A et al.: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 56:671–676.
  • LIU X, YAO S, KIRSCHENBAUM A, LEVINE A: NS-398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bc1-2 expression in lncap cells. Cancer Res. (1998) 58:4245–4249.
  • LIM J, PIAZZA G, HAN E et al: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol (1999) 58:1097–1107.
  • ATTIGA F, FERNANDEZ P, WEERARATNA A, MANYAK M, PATIERNO S: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. (2000) 60:4629–4637.
  • HOWE L, SUBBARAMAIAH K, BROWN A, DANNENBERG A: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer (2001) 8:97–114.
  • HWANG D, SCOLLARD D, BYRNE J, LEVINE E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J. Nati Cancer Inst. (1998) 90:455–460.
  • BROWN P, LIPPMAN S: Chemoprevention of breast cancer. Breast Cancer Res. Treat. (2000) 62:1–17.
  • •Examines COX-2 inhibitors and other strategies for the prevention of breast cancer.
  • SUBBARAMAIAH K, NORTON L, GERALD W, DANNENBERG A: Cyclooxygenase-2 is overexpressed in her-2/ neu-positive breast cancer:Evidence for involvement of ap-1 and pea3. j. Biol. Chem. (2002) 277:18649–18657.
  • •Examines the relationship between HER-2/neu status and COX-2 expression in human breast tumours.
  • SOSLOW R, DANNENBERG A, RUSH D et al:Cox-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (2000) 89:2637–2645.
  • SHIRAHAMA T, SAKAKURA C: Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clio. Cancer Res. (2001) 7:558–561.
  • SHIRAHAMA T: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clio. Cancer Res. (2000) 6:2424–2430.
  • RISTIMAKI A, NIEMINEN 0, SAUKKONEN K, HOTAKAINEN K, NORDLING S, HAGLUND C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol (2001) 158:849–853.
  • TIGUERT R, LESSARD A, SO A, FRADET Y: Prognostic markers in muscle invasive bladder cancer. World j Urol. (2002) 20:190–195.
  • KOMHOFF M, GUAN Y, SHAPPELL H et al.: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am. J. Pathol (2000) 157:29–35.
  • MOHAMMED S, KNAPP D, BOSTWICK D et al.: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. (1999) 59:5647–5650.
  • GEE J, SABICHI A, GROSSMAN H: Chemoprevention of superficial bladder cancer. Crit. Rev. Oncol Hematol (2002) 43:277.
  • WEI M, WANIBUCHI H, MORIMURA K et al.: Carcinogenicity of dimethylarsinic acid in male f344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis (2002) 23:1387–1397.
  • KITAYAMA W, DENDA A, OKAJIMA E, TSUJIUCHI T, KONISHI Y: Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis (1999) 20:2305–2310.
  • GRUBBS C, LUBET R, KOKI A et al: Celecoxib inhibits N-butyl-N-(4-hydroxybuty0-nitrosamine-induced urinary bladder cancers in male b6d2f1 mice and female fischer-344 rats. Cancer Res. (2000) 60:5599–5602.

Websites

  • http://www.centerwatch.com CenterWatch: Clinical Trials Listing Service7
  • http://cancernet.nci.nih.gov/trailsrch.shtml National Cancer Institute; Cancer.gov (cancer information).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.